## 1. INTRODUCTION

Penile cancer is a rare cancer in developed countries, but it has a higher incidence in developing countries such as Asia, Africa, and South America\(^1,2\). Despite its rarity, the disease significantly affects the patient’s life when it does occur. Localized disease can be managed by surgical resection (partial or total penectomy) or penis-preserving surgery and radiotherapy. In patients with a higher T stage or grade, or clinically positive inguinal lymph nodes, an inguinal lymph node dissection is usually performed. If nonregional lymph nodes are involved or if metastatic disease is present, surgical cure cannot be obtained.

In these cases of advanced disease, surgery with or without radiation is often used for palliation and local control. Metastatic disease, which can involve distant lymph nodes, lung, liver, brain, and bone, is often managed with chemotherapy. Chemotherapy in this situation has been poorly studied (no randomized trials), responses are often partial and of short duration, and therapy is associated with significant toxicity\(^3-7\). Thus, it is imperative that new therapies be investigated for this rare but devastating disease.

Since the end of the 1980s, an understanding of the molecular biology of cancer has immensely increased the understanding of tumour biology. Using this knowledge, scientists and clinicians are turning to novel treatments to exploit specific molecular targets. Tumour growth and progression depend on a number of pathways involving receptors at the cell membrane surface that control intracellular signalling pathways. One important pathway involves the cell-surface receptor epidermal growth factor receptor (EGFR)\(^8\). Epidermal growth factor and other ligands bind to and activate EGFR to activate signalling pathways that regulate cell proliferation, migration, adhesion, differentiation, and apoptosis.

In a number of solid tumours, including brain, lung, breast, prostate, stomach, and head and neck, EGFR can be overexpressed or mutated, leading to deregulation of related pathways. Overstimulation of EGFR-mediated signalling can contribute to uncontrolled cell division and thus to oncogenic signalling and tumour angiogenesis and metastasis, protecting cancer cells from undergoing apoptosis. In some malignancies, overexpression or excessive activation of EGFR tends to be associated with a more aggressive malignant phenotype, with greater metastatic potential and worse prognosis\(^9-11\).

To our knowledge, no studies have evaluated the expression of EGFR in invasive squamous cell carcinoma of the penis. Given EGFR overexpression, and the success with EGFR-directed therapy in other tumours, we felt it worthwhile to pursue this area of research in penile cancer. Thus, the objective of the present study was to characterize the expression of EGFR in cases of invasive squamous cell carcinoma of the penis. If overexpression were to be seen, then exploiting the EGFR pathway as a therapeutic target in advanced penile cancer would be a rational approach.

## 2. MATERIALS AND METHODS

Approval from the local research ethics board was obtained. Samples were selected from a pathology database of invasive penile squamous cell carcinoma obtained through biopsy or surgical resection at the QEII Health Sciences Center, Halifax, during 1997–2004.

Expression of EGFR was evaluated and graded (0, 1+, 2+, 3+) by one trained pathologist using guidelines outlined in the commercially available immunohistochemical system kit EGFR PharmDx (DakoCytomation, Carpinteria, CA, U.S.A.). We used the EGFR PharmDx monoclonal mouse antibody (clone 2-18C9) with controls consisting of human cell lines CAMA-1 (negative control) and HT29 (positive control). Overexpression of EGFR in the primary penile cancer was defined as any immunohistologic staining of tumour cell membranes above background level, whether circumferential staining was complete or
incomplete. No information on lymph node staging, lymphadenectomies, or EGFR expression in lymph nodes was obtained.

3. RESULTS

From the selected 8-year time period, 17 cases were obtained and studied. The median age of all patients was 66 years (range: 46–95 years).

All 17 cases overexpressed EGFR (Table 1, Figure 1). Expression was 3+ in 14 cases and 2+ in 3 cases. Of the samples examined, 4 cases were also associated with carcinoma in situ (CIS). In 2 cases, the CIS also overexpressed EGFR, but to a lesser degree (1+) than did the invasive component. In the other 2 cases, the CIS did not overexpress EGFR.

In all cases, the adjacent normal squamous epithelium demonstrated normal background EGFR expression. Table 1 also presents the pathologic T stage and grade, but because overexpression of EGFR was seen in all samples, no associations can be made between stage, grade, and overexpression.

Limitations to this study include its small sample size, which limited our ability to make any comments or conclusions about associations with T stage and grade. Also, we did not obtain information on lymph node metastases or measure the phosphorylated form of EGFR.

4. DISCUSSION AND CONCLUSIONS

Therapeutic advances in the area of advanced or metastatic penile cancer have been limited for several decades. Managing patients with this disease is a frustrating and disappointing endeavour because only short-lived partial responses can be obtained using traditional chemotherapy drugs.

Every sample of invasive squamous cell carcinoma of the penis evaluated in this study expressed EGFR, with most showing 3+ overexpression. To date, several EGFR-targeted therapies have been developed. These include monoclonal antibodies that bind to EGFR ligands (for example, cetuximab) and EGFR tyrosine kinase inhibitors (for example, gefitinib, erlotinib). As single agents, these drugs have been shown to have activity in several solid tumours including lung, head and neck, and colon 12–16. In phase I and II lung and colon cancer trials, overall survival was improved. Current research is ongoing in these tumours to study the effects of chemotherapy in combination with EGFR-targeted therapy to improve outcomes even more.

Given the positive results in other tumours, the high degree of EGFR overexpression in all samples in this study, and the lack of effective treatment for advanced penile cancer, further research into the EGFR pathway and invasive penile cancer are warranted. For example, determining whether lymph node or distant metastases from penile cancer also overexpress EGFR would be worthwhile, as would determining whether EGFR-targeted therapy has clinical activity in the setting of advanced disease.

5. ACKNOWLEDGMENT

Our thanks go to Sandra Bellefontaine for administrative assistance.

6. REFERENCES

1. Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR. Incidence trends in primary malignant penile cancer. Urol Oncol 2007;25:361–7.
2. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer Incidence in Five Continents [CD ROM], Vols. I–VIII. International Agency for Research on Cancer (IARC) CancerBase series no. 7. Lyon, France: IARC Press; 2005.

3. Ahmed T, Sklaroff R, Yagoda A. Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer. J Urol 1984;132:465–8.

4. Gagliano RG, Blumenstein BA, Crawford ED, Stephens RL, Coltman CA Jr, Costanzo JJ. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol 1989;141:66–7.

5. Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol 1998;160:1770–4.

6. Haas GP, Blumenstein BA, Gagliano RG, et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999;161:1823–5.

7. Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992;147:630–2.

8. Wells A. EGFR receptor. Int J Biochem Cell Biol 1999;31:637–43.

9. Aaronson SA. Growth factors and cancer. Science 1991;254:1146–53.

10. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 1995;19:183–232.

11. Mendelsohn J, Baselga J. The EGFR receptor family as targets for cancer therapy. Oncogene 2000;19:6550–65.

12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. on behalf of the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.

13. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980–7.

14. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77–85.

15. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171–7.

16. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040–8.

Correspondence to: Lori Wood, Division of Medical Oncology, QEII Health Sciences Centre, Room 471, Bethune Building, 1278 Tower Road, Halifax, Nova Scotia B3H 2Y9.

E-mail: lori.wood@cdha.nshealth.ca

* Urology Department, QEII Health Sciences Centre, Halifax, NS.
† Department of Anatomical Pathology and Laboratory Medicine, QEII Health Sciences Centre, Halifax, NS.
‡ Division of Medical Oncology, QEII Health Sciences Centre, Halifax, NS.